Clinical Trials in Houston

Showing 14881-14900 of 17,885 trials

Assessmet of Patients With PAH Right Ventricular Volume

NCT01557582

The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with Pulmonary Arterial Hypertension (PAH). The trial will be defined as positive if the mean VMS-cMRI percent difference is \<10% and \>-10% at a 1-sided 0.025 statistical significance level for RVEDV and for RVESV, with no safety concerns for the VMS procedure.

Pulmonary Arterial Hypertension

VentriPoint Diagnostics Ltd.103 participantsStarted Apr 2012

Chicago, Illinois, United States • Boston, Massachusetts, United States • Rochester, Minnesota, United States +4 more locations

COMPLETED< 1 mile

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

NCT00989313

This study is designed to follow up patients, who have participated in the PEP005-028 study and observed complete clearance of their Actinic Keratosis (AK) lesions, over a 12 month period to assess both recurrence of AK lesions and long term safety in the selected treatment area.

Actinic Keratosis

Peplin43 participantsStarted Sep 2009

Hot Springs, Arizona, United States • San Diego, California, United States • Alpharetta, Georgia, United States +14 more locations

Assessmet of Patients With PAH Right Ventricular Volume

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

Find Trials by Condition in Houston

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Dose Ranging Study

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Family Eats:Cancer Prevention for Families

A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Phase IIIB Subcutaneous Abatacept Monotherapy Study

The BRILLIANT Study

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme